In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Millennium to merge BioTherapeutics

Executive Summary

Millennium Pharmaceuticals will purchase the outstanding stock it doesn't already own in its Millennium BioTherapeutics subsidiary from Eli Lilly, which invested $20mm two-and-a-half years ago for an 18% stake. Millennium will issue Lilly about 360,000 shares of its own stock (worth $5.4mm at its $15 market price). Millennium will also issue 380,000 shares for current BioTherapeutics options that will be converted to options to buy Millennium stock.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Partial Acquisition

Related Companies